European Journal of Nuclear Medicine and Molecular Imaging

Article	Citations
New technologies—the best is yet to come	217
Nuclear imaging and therapy in oncology in Poland in 2021–2022	167
Synthesis and preclinical evaluation of [18F]AlF-NOTA-Asp2-PEG2-JR11 as a novel antagonist radioligand for PET imaging of somatostatin receptor	145
Individual-level metabolic connectivity from dynamic [18F]FDG PET reveals glioma-induced impairments in brain architecture and offers novel insights beyond the SUVR clinical standard	138
Comparison of [18F]FAPI-42 and [18F]FDG PET/CT in the evaluation of systemic vasculitis	136
PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE – first clinical experiences	123
Tumor agnostic ultrasmall nanoprobes for fluorescence-guided surgical resection in peritoneal metastasis	115
Hybrid cardiovascular imaging. A clinical consensus statement of the european association of nuclear medicine (EANM) and the european association of cardiovascular imaging (EACVI) of the ESC	107
Persistent dysfunctions of brain metabolic connectivity in long-covid with cognitive symptoms	105
Identification of metabolic progression and subtypes in progressive supranuclear palsy by PET molecular imaging	98
This union must happen: Radiomics and LAFOV PET/CT as the power couple of nuclear medicine	97
New EAU/ASCO guideline recommendations on sentinel node biopsy for penile cancer and remaining challenges from a nuclear medicine perspective	96
The world of functional and molecular imaging is not only based on radiopharmaceuticals: may EJNMMI become the house of all the images’ interpreters?	90
A deep learning model for generating [18F]FDG PET Images from early-phase [18F]Florbetapir and [18F]Flutemetamol PET images	89
Cinematic rendering of [18F]FDG-PET/MR	89
Diagnostic efficiency of [68 Ga]Ga-DOTA-FAPI-04 in differentiating periprosthetic hip joint infection and aseptic failure	83
Brain perfusion estimation by Tikhonov model-free deconvolution in a long axial field of view PET/CT scanner exploring five different PET tracers	83
Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients	78
A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands	76
An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases	71
EANM Springer Prizes 2021 awarded at EANM 2021	71
A first-in-human study of 11C-MTP38, a novel PET ligand for phosphodiesterase 7	70
ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053	69
A novel deep-learning–based approach for automatic reorientation of 3D cardiac SPECT images	69
Cancer photodynamic therapy with chlorin e6-loaded, goat milk-derived extracellular vesicles: [18F]FDG lights up the way	68

Head-to-head comparison of (R)-[11C]verapamil and [18F]MC225 in non-human primates, tracers for measuring P-glycoprotein function	68
D. Taïeb and K. Pacak (Eds). Current Diagnostic and Therapeutic Approaches in Nuclear Endocrinology	67
Looking ahead	67
Unmasking disseminated streptococcal infection: role of FDG PET/CT in diagnosis and assessing response to antibiotic treatment	66
On the factors affecting the liver SUV in [18F]FDG PET/CT imaging	66
Neural correlates of beneficial effects of young plasma treatment in aged mice: PET-SPM analyses and neuro-behavioural/molecular biological studies	65
EANM Springer Prizes 2020 awarded at EANM 2021	65
Unsupervised [18F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease	65
64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer	63
“Metabolic fingerprints” of cachexia in lung cancer patients	63
PET/MRI in practice: a clinical centre survey endorsed by the European Association of Nuclear Medicine (EANM) and the EANM Forschungs GmbH (EARL)	62
Yelda Özsunar, Utku Senol (Eds.). Atlas of Clinical Cases on Brain Tumor Imaging	62
Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier	61
Response to the letter to the Editor by Professors Francesco Giammarile and Stefano Fanti regarding our article “Survey by the ANSM of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11	59
[18F] AlF‑NOTA‑FAPI‑04 PET/CT as a promising tool for imaging fibroblast activation protein in gastrointestinal system cancers: a prospective investigation of comparative analysis with 18F-FDG	59
First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner	58
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer	58
Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings	57
Preclinical evaluation of a dual-receptor targeted tracer [68Ga]Ga-HX01 in 10 different subcutaneous and orthotopic tumor models	57
CYP3A4 inhibitors may influence the quantification of [123I]I-FP-CIT SPECT scans	56
Finding our way through the labyrinth of dementia biomarkers	56
Mosaic pattern of skin granuloma annulare on [18F]FDG PET/CT	54
Feasibility of acquisitions using total-body PET/CT with a half-dose [68Ga]Ga-FAPI-04 activity in oncology patients	53
Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma	52
Ultra-short time imaging of total-body PET/CT for cancer pain-induced untenable body position	51
FDG-PET/CT for investigation of pyrexia of unknown origin: a cost of illness analysis	51
Development of probes for radiotheranostics with albumin binding moiety to increase the therapeutic effects of astatine-211 (211At)	50
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies	50
Federico Caobelli (Ed): Imaging of Inflammation and Infection in Cardiovascular Diseases	49
A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer	48
The validation of low-dose CT scans from the [18F]-FDG PET-CT scan to assess skeletal muscle mass in comparison with diagnostic neck CT scans	48
Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand the	47
Low-dose dobutamine stress gated blood pool SPECT assessment of left ventricular contractile reserve in ischemic cardiomyopathy: a feasibility study	47
Deep learning–based whole-body characterization of prostate cancer lesions on [68Ga]Ga-PSMA-11 PET/CT in patients with post-prostatectomy recurrence	47
High-resolution radioluminescence microscopy of FDG uptake in an engineered 3D tumor-stoma model	47
The EANM guideline on radioiodine therapy of benign thyroid disease	47
Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma	46
Quantitative analysis of myocardial blood flow in surgically revascularized and not revascularized myocardial segments. A pilot PET study	46
Staging 68 Ga-PSMA PET/CT in 963 consecutive patients with newly diagnosed prostate cancer: incidence and characterization of skeletal involvement	46
[18F]mFBG long axial field of view PET-CT without general anaesthesia reveals concise extension of neuroblastoma in a 9-month-old boy	46
Spatiotemporal dynamics of brain function during the natural course in a dental pulp injury model	46
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?	45
Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study	45
Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma—a proof of concept study	45
Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI	45
Biodistribution and radiation dosimetry in cancer patients of the ascorbic acid analogue 6-Deoxy-6-[18F] fluoro-L-ascorbic acid PET imaging: first-in-human study	44
Controversies of [68Ga]Ga-FAPI-46 and 2-[18F]FDG findings in metastatic melanoma	44
The additional role of [68Ga]Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F]FDG	44
External validation of an 18F-FDG-PET radiomic model predicting survival after radiotherapy for oropharyngeal cancer	44
Proliferation and apoptosis after whole-body irradiation: longitudinal PET study in a mouse model	44

The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study	44
Regional myocardial perfusion imaging in predicting vessel-related outcome: interplay between the perfusion results and angiographic findings	43
Reducing instability of inter-subject covariance of FDG uptake networks using structure-weighted sparse estimation approach	43
State-of-the-art of nuclear medicine and molecular imaging in China: after the first 66 years (1956–2022)	42
The status of nuclear medicine in China: the first official national survey	41
Cadherin-17 as a target for the immunoPET of adenocarcinoma	40
Machine learning identifies multi-parametric functional PET/MR imaging cluster to predict radiation resistance in preclinical head and neck cancer models	40
The role of [18 F]FDOPA PET as an adjunct to conventional MRI in the diagnosis of aggressive glial lesions	40
Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition	40
[68 Ga]Ga-FAPI versus [18F]F-FDG in malignant melanoma: complementary or counterpoint?	39
Hossein Jadvar and Patrick M. Colletti (Eds): Nuclear Medicine: the Essentials	39
Can 68Ga-PSMA-11 PET/CT predict pathological upgrading of prostate cancer from MRI-targeted biopsy to radical prostatectomy?	39
Alberto Signore (Editor-in-Chief) Nuclear medicine and molecular imaging	38
Errors in imaging reading and reporting	38
Improved diagnostic accuracy for coronary artery disease detection with quantitative 3D 82Rb PET myocardial perfusion imaging	38
“Fuzzy” radiomics: the way forward for nuclear medicine imaging applications?	38
Long-term impact of myocardial inflammation on quantitative myocardial perfusion—a descriptive PET/MR myocarditis study	38
IE-CycleGAN: improved cycle consistent adversarial network for unpaired PET image enhancement	37
Multiple myeloma mimicking metastatic skull base paraganglioma in [68 Ga]Ga-DOTATOC-PET/CT and 2-[18F]FDG-PET/CT imaging	37
Evaluating the efficacy of [177Lu]Lu-FAP-2286 in combination therapy for metastatic breast cancer	37
First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients	36
Minutes to hours after a nuclear event: available radiation poisoning antidotes and practical considerations on possible urgent approaches	36
EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)	36
PSMA PET/CT cost-effectiveness analysis in the USA: a response to a published commentary	36
Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET	35
Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes	35
Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study	35
[68Ga]Ga-FAPI versus [18F]FDG PET/CT in the evaluation of Langerhans cell histiocytosis	35
Determining the optimal pharmacokinetic modelling and simplified quantification method of [18F]AlF-P16-093 for patients with primary prostate cancer (PPCa)	35
The ICPO Foundation—on the way toward collaborative growth of theranostics	34
Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management	34
[68Ga]Ga-Pentixafor PET/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: correlation with quantitative receptors’ density by immunochemistry techniques	34
Successful radioiodine redifferentiation with selpercatinib in RET fusion-positive papillary thyroid carcinoma	34
Validation and utility of HepG2 xenograft model for hepatocellular carcinoma	33
Trigeminal nerve perineural invasion by an adenoid cystic carcinoma of the maxillary sinus, detected by 68Ga-PSMA	33
Unified spatial normalization method of brain PET images using adaptive probabilistic brain atlas	33
68Ga-FAPI PET/CT detected non-FDG-avid bone metastases in breast cancer	33
Early, non-invasive detection of radiation-induced lung injury using PET/CT by targeting CXCR4	33
Machine learning radiomics to predict the early recurrence of intrahepatic cholangiocarcinoma after curative resection: A multicentre cohort study	33
Unique [18F]FDG PET imaging pattern of drug-induced acute generalized exanthematous pustulosis within the SCAR-spectrum	33
Higher accuracy of [68 Ga]Ga-DOTA-FAPI-04 PET/CT comparing with 2-[18F]FDG PET/CT in clinical staging of NSCLC	33
Simultaneous high-resolution whole-brain MR spectroscopy and [18F]FDG PET for temporal lobe epilepsy	32
Advanced imaging findings in stroke-like migraine attacks after radiation therapy (SMART) syndrome	32
Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients	32
Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging	32
Reducing the risks of nuclear war—the role of health professionals	32
Granzyme B PET imaging inflammation and remodeling in myocardial infarction	32
Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting	32
Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain	32
Nuclear imaging in the new ESC Guidelines: the age of maturity	32
Luca Giovanella. Integrated Diagnostics and Theranostics of Thyroid Diseases	32
EANM-Springer Award winners 2023	32
[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial	31
Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus	31
EANM procedural recommendations for managing the paediatric patient in diagnostic nuclear medicine	31
Development and external validation of a multivariable [68Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer	31
Comments to “Survey by the ANSM of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT”	31
Three-way multiplexing in prostate cancer patients — combining a bimodal sentinel node tracer with multicolor fluorescence imaging	31
Segmentation of white matter hyperintensities on 18F-FDG PET/CT images with a generative adversarial network	31
Impact of the COVID-19 pandemic on nuclear medicine departments in Europe	31
[68 Ga]Ga-DOTATATE PET/CT versus [68 Ga]Ga-Exendin-4 PET/CT in the evaluation of metastatic insulinoma	31
Sex-based differences in nuclear medicine imaging and therapy	31
Pharmacokinetic and pharmacodynamic assessment of histamine H3 receptor occupancy by enerisant: a human PET study with a novel H3 binding ligand, [11C]TASP457	30
99mTc‑labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types	30
Can we use PET to quantify mu opioid receptors across the monkey brain, spinal cord and peripheral organs at the same time? Totally!	30
PET/CT imaging with radiolabeled FAPI: new opportunities for diagnosis and treatment of thyroid cancer	30
Nuclear medicine practice for the assessment of cardiac sarcoidosis and amyloidosis. A survey endorsed by the EANM and EACVI.	30
The role of [68 Ga]Ga-FAPI-04 PET/CT in renal cell carcinoma: a preliminary study	30
Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [11C]-PBR28 blocking study	30
Seasonal variation in D2/3 dopamine receptor availability in the human brain	29
Diagnostic accuracy of anti-3-[18F]-FACBC PET/MRI in gliomas	29
PD-L1 − targeted magnetic fluorescent hybrid nanoparticles: Illuminating the path of image-guided cancer immunotherapy	29
Assessment of [18F]PI-2620 Tau-PET Quantification via Non-Invasive Automatized Image Derived Input Function	29
Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation	29
Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies	29
Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease: additional results from the AMBAR study	29
FAPI PET/CT: a new kid on the block for RCC	29
68Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement	28
Direct inference of Patlak parametric images in whole-body PET/CT imaging using convolutional neural networks	28
Anne G. Osborn, Luke L. Linscott, Karen L. Salzman: Osborn’s Brain: Imaging, Pathology and Anatomy, 3rd Edition	28

How to combine CTA, 99mTc-WBC SPECT/CT, and [18F]FDG PET/CT in patients with suspected abdominal vascular endograft infections?	28
Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor	28
Convolutional neural networks for PET functional volume fully automatic segmentation: development and validation in a multi-center setting	28
On the rational use of thyroid scintigraphy in thyrotoxic patients in the age of integrated diagnostics	28
Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis	28
Challenges coexist with opportunities: development of a macrocyclic peptide PET radioligand for PD-L1	28
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective	28
Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial	28
EC50 images, a novel endpoint from PET target occupancy studies, reveal spatial variation in apparent drug affinity	28
Radiopharmaceutical need between the clinic and regulatory agencies: how philosophy could explain 'the road taken'	28
Role of sex hormones in modulating myocardial perfusion and coronary flow reserve	27
Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent	27
Three-dimensional spatial localization and volume estimation of prostate tumors using 18F-PSMA-1007 PET/CT versus multiparametric MRI	27
A case of cerebral amyloid angiopathy with ipsilateral tau and contralateral amyloid PET uptake related to cadaveric dura mater implanted in childhood	27
3D voxel-based dosimetry to predict contralateral hypertrophy and an adequate future liver remnant after lobar radioembolization	27
Intriguing information from recent letter and article regarding unwanted targeting of salivary glands by PSMA ligands	26
Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial	26
Tau aggregation following subcortical hemorrhage	26
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum	26
Towards molecular imaging-guided intervention theatres in oncology	26
ImmunoPET imaging–based pharmacokinetic profiles of an antibody and its Fab targeting endothelin A receptors on glioblastoma stem cells in a preclinical orthotopic model	26
Artificial intelligence guided enhancement of digital PET: scans as fast as CT?	26
How nuclear imaging changed parathyroid surgical strategies through time	26
The feasibility of ultra-early and fast total‑body [68 Ga]Ga-FAPI-04 PET/CT scan	26
Retrospective analysis of PSMA PET/CT thyroid incidental uptake in adults: incidence, diagnosis, and treatment/outcome in a tertiary cancer referral center and University Medical Center	26
International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology	26
Postoperative [68Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1	26
The value of bone SPECT/CT in evaluation of foot and ankle arthrodesis and adjacent joint secondary osteoarthritis	26
Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study	26
Letter to the editor concerning “Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor”	26
Is it time to include [18F]FDG-PET/CT in the diagnostic work-up for lymph node staging in cN0 vulvar cancer patients?	26
Homodimeric peptide radiotracer [68Ga]Ga-NOTA-(TMVP1)2 for VEGFR-3 imaging of cervical cancer patients	25
About the source and consequences of 18F-FDG brain PET hypometabolism in short and long COVID-19	25
Head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]FDG PET/CT in multiple myeloma	25
68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results	25
A novel PSMA targeted dual-function near-infrared fluorescence and PET probe for the image-guided surgery and detection of prostate cancer	25
Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study	25
Towards in vivo characterization of thyroid nodules suspicious for malignancy using multispectral optoacoustic tomography	25
Deep learning–based time-of-flight (ToF) image enhancement of non-ToF PET scans	25
Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison	25
Machine learning in the differentiation of follicular lymphoma from diffuse large B-cell lymphoma with radiomic [18F]FDG PET/CT features	24
TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET/CT images — a multi-center generalizability analysis	24
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer	24
18F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy	24
Total-body PET/CT or LAFOV PET/CT? Axial field-of-view clinical classification	24
Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers	24
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial	24
Assessment of myocardial fibrosis in patients with systemic sclerosis using [68Ga]Ga-FAPI-04-PET-CT	24
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer	24
[99mTc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience	24
[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment	23
Radioiodinated Nanobody immunoPET probe for in vivo detection of CD147 in pan-cancer	23
The feasibility of quantitative assessment of dynamic 18F-fluorodeoxyglucose PET in Takayasu’s arteritis: a pilot study	23
[68Ga]Ga-FAPI-04 PET/CT in the evaluation of epithelial ovarian cancer: comparison with [18F]F-FDG PET/CT	23
TSPO imaging in animal models of brain diseases	23
Sex differences in coronary atherosclerotic plaque activity using 18F-sodium fluoride positron emission tomography	23
Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation	23
Short-axis PET image quality improvement based on a uEXPLORER total-body PET system through deep learning	23
PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions	23
Comparison of clinical performance between late and standard total-body [68 Ga]Ga-PSMA-11 in biochemical recurrent prostate cancer	23
Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopa	23
Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence	23
GCP III is not the “off-target” for urea-based PSMA ligands	23
Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics	22
Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study	22
Nuclear cardiology a solid pillar in the new chronic coronary syndromes ESC guidelines	22
FAP expression in alpha cells of Langherhans insulae—implications for FAPI radiopharmaceuticals’ use	22
[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies	22
Fluorophore-conjugated 4-1BB antibody enables early detection of T-cell responses in inflammatory arthritis via NIRF imaging	22
Position paper of the EACVI and EANM on artificial intelligence applications in multimodality cardiovascular imaging using SPECT/CT, PET/CT, and cardiac CT	22
Targeting CXCR4/CXCL12 axis via [177Lu]Lu-DOTAGA.(SA.FAPi)2 with CXCR4 antagonist in triple-negative breast cancer	22
Multicentric development and evaluation of 18F-FDG PET/CT and MRI radiomics models to predict para-aortic lymph node involvement in locally advanced cervical cancer	22
Joint EANM/SNMMI guideline on radiomics in nuclear medicine	21
Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound	21
Preclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging	21
Ultra-fast high resolution whole-body SPECT after treatment with 153Sm-EDTMP using 3D-ring CZT: applying new technology to an old tracer	21
FAPI PET/CT in infectious, inflammatory, and rheumatological diseases: “watch it like a hawk” or “one swallow does not make a summer”?	21
Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms	21
PET molecular imaging for pathophysiological visualization in Alzheimer’s disease	21
Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine	21
Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0	21
FAPI PET for monitoring of rheumatological treatment in multifocal peritoneal nodular fibrosis: a case study	21
Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study	21
Preclinical evaluation of EpCAM-binding designed ankyrin repeat proteins (DARPins) as targeting moieties for bimodal near-infrared fluorescence and photoacoustic imaging of cancer	21
[18F]-FDG PET in anal canal cancer: a systematic review and meta-analysis	21
The false myth of “iodine allergy” also in nuclear medicine	21
Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum	21
State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis	21
GPC3-targeted immunoPET imaging of hepatocellular carcinomas	21
Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [18F]FDG PET/CT imaging: quantitative analysis of [18F]FDG uptake in primary tumo	21
Radiomics in pancreatic neuroendocrine tumors: methodological issues and clinical significance	20
Long axial field of view PET scanners: a road map to implementation and new possibilities	20
Intraoperative fluorescence molecular imaging accelerates the coming of precision surgery in China	20
Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group	20
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model	20